March 16, 2012 - Cambridge Heart Inc., a developer of non-invasive diagnostic tests for cardiac disease, announced that its Microvolt T-Wave Alternans (MTWA) test received reimbursement coverage from Japan’s Ministry of Health, Labor and Welfare (MHLW). Effective April 1, 2012, the MTWA Test will be reimbursed for patients who are considered at risk for lethal arrhythmias including, but not limited to, patients with a history of heart attack, cardiomyopathy and Brugada syndrome.
